2. Search Result
Search Result
Results for "

High-density lipoprotein cholesterol

" in MedChemExpress (MCE) Product Catalog:

32

Inhibitors & Agonists

2

Peptides

1

Inhibitory Antibodies

1

Natural
Products

3

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P6306
    CS-6253
    1 Publications Verification

    		 Apolipoprotein Amyloid-β Neurological Disease Metabolic Disease
    CS-6253 is an agonist of ABCA1. CS-6253 can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
    CS-6253
  • HY-126573
    Trilaurin

    		Endogenous Metabolite Biochemical Assay Reagents Cardiovascular Disease Metabolic Disease Cancer
    Trilaurin is an orally active triglyceride. Trilaurin inhibits DMBA-induced, croton oil-promoted skin tumor formation in Swiss Webster mice. Trilaurin increases plasma high-density lipoprotein cholesterol and apolipoprotein A-I concentrations. Trilaurin is used as an occlusive skin conditioning agent and/or non-aqueous thickener in cosmetics .
    Trilaurin
  • HY-153491
    Olezarsen

    ISIS 678354; IONIS-APOCIII-LRx; AKCEA-APOCIII-LRx

    		 Apolipoprotein Cardiovascular Disease
    Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) is a GalNAc-modified antisense oligonucleotide. Olezarsen binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
    Olezarsen
  • HY-117549
    Ibrolipim

    NO-1886

    		 Lipase Cardiovascular Disease
    Ibrolipim (NO-1886) is an orally active lipoprotein lipase (LPL)-promoting agent. Ibrolipim decreases plasma triglycerides, increases high-density lipoprotein cholesterol levels. Ibrolipim has renoprotective and hypolipidemic effects .
    Ibrolipim
  • HY-109567
    Gemcabene

    PD-72953

    		 LDLR Metabolic Disease Inflammation/Immunology
    Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene
  • HY-P99822
    Recaticimab

    SHR-1209

    		 PCSK9 Metabolic Disease
    Recaticimab (SHR-1209) is a humanized IgG1 mAb that selectively targets PCSK9. Recaticimab reduces low-density lipoprotein cholesterol (LDL-C), non-high-density lipoprotein cholesterol (non-HDL-C), apolipoprotein B (ApoB), triglyceride (TG), and lipoprotein(a) levels. Recaticimab can be used for hyperlipidemia research .
    Recaticimab
  • HY-12089
    Torcetrapib

    CP-529414

    		 CETP Endocrinology
    Torcetrapib (CP-529414) is a selective, potent cholesteryl ester transfer protein (CETP) inhibitor. A typical inhibition curve for whole human plasma, having a CETP concentration of 37 nM .
    Torcetrapib
  • HY-153491A
    Olezarsen sodium

    ISIS 678354 sodium; IONIS-APOCIII-LRx sodium; AKCEA-APOCIII-LRx sodium

    		 Apolipoprotein Cardiovascular Disease
    Olezarsen (ISIS 678354;IONIS-APOCIII-LRx) sodium is a GalNAc-modified antisense oligonucleotide. Olezarsen sodium binds to APOC3 mRNA and induces its degradation via ribonuclease H1-mediated sense strand cleavage, thereby reducing hepatic apolipoprotein C-III (apoC-III) synthesis. Olezarsen sodium reduces plasma triglyceride, apolipoprotein B and non-high-density lipoprotein cholesterol levels. Olezarsen sodium is applicable to research related to familial chylomicronemia syndrome, hypertriglyceridemia and atherosclerotic cardiovascular disease .
    Olezarsen sodium
  • HY-100469
    LXRβ agonist-2

    		LXR Inflammation/Immunology
    LXRβ agonist-2 is an orally active and selective LXRβ agonist. LXRβ agonist-2 increases high-density lipoprotein cholesterol levels without elevating plasma triglyceride levels. LXRβ agonist-2 decreases lipid accumulation area in the aortic arch. LXRβ agonist-2 can be used for the research of atherosclerosis .
    LXRβ agonist-2
  • HY-121212
    Icosabutate

    		LDLR Metabolic Disease Inflammation/Immunology
    Icosabutate, an orally active ω-3 polyunsaturated fatty acid, is an aeicosapentaenoic acid (EPA) derivative. Icosabutate overcomes the drawbacks of unmodified EPA for liver targeting and improves insulin sensitivity, hepatic inflammation and fibrosis . Icosabutate is well tolerated, and efficacious in lowering non-high-density lipoprotein cholesterol (non-HDL-C) levels in persistent hypertriglyceridemia .
    Icosabutate
  • HY-P6306A
    CS-6253 TFA
    1 Publications Verification

    		 Apolipoprotein Amyloid-β Neurological Disease Metabolic Disease
    CS-6253 TFA is an agonist of ABCA1. CS-6253 TFA can regulate lipoprotein metabolism, promote high-density lipoprotein biogenesis, and cellular cholesterol efflux. CS-6253 TFA also has certain neuroprotective effects and can clear Aβ from the brain. CS-6253 TFA can be used for research on cholesterol metabolism and diseases such as Alzheimer’s disease .
    CS-6253 TFA
  • HY-165061
    5(Z),11(Z),14(Z)-Eicosatrienoic acid

    Sciadonic acid

    		 Apolipoprotein Inflammation/Immunology
    5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
    5(Z),11(Z),14(Z)-Eicosatrienoic acid
  • HY-176817
    GPR109 receptor agonist-3

    		GPR109A Cardiovascular Disease Metabolic Disease
    GPR109 receptor agonist-3 is an orally active GPR109 receptor agonist, with an IC50 of 310 nM. GPR109 receptor agonist-3 retains the antioxidation and cytoprotection of Lipoic acid (HY-18733). GPR109 receptor agonist-3 reduces total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and increases high-density lipoprotein cholesterol (HDL-C) in high-fat diet-fed rats. GPR109 receptor agonist-3 can be used for the study of atherosclerosis .
    GPR109 receptor agonist-3
  • HY-19852
    KRP-105

    		PPAR Metabolic Disease
    KRP-105 is a potent, highly selective, and orally effective PPAR alpha (EC50 = 8 nM) agonist. KRP-105 can significantly reduce serum triglyceride, total cholesterol, and non high density lipoprotein cholesterol levels. KRP-105 can be used for research on metabolic diseases such as dyslipidemia .
    KRP-105
  • HY-123039
    CP-532623

    		CETP Metabolic Disease
    CP-532623 is a CETP inhibitor and elevates high-density lipoprotein cholesterolion. CP-532623 is a close structural analogue of Torcetrapib. CP-532623 has highly lipophilic properties .
    CP-532623
  • HY-115914
    Lipid-lowering agent-1

    		LDLR Others
    Lipid-lowering agent-1 is a potent lipid-lowering agent. Lipid-lowering agent-1 has significant pharmacological effects on the inhibition of low-density lipoprotein cholesterol (LDLC) and promotion of high-density lipoprotein cholesterol (HDLC) production. Lipid-lowering agent-1 shows potent hypolipidemic effect in high-fat diet rats .
    Lipid-lowering agent-1
  • HY-100902
    CDD3506

    		Cytochrome P450 Metabolic Disease
    CDD3506 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
    CDD3506
  • HY-169723
    CP 524515

    		CETP Metabolic Disease
    CP 524515 is a potent inhbitor of cholesteryl ester transfer protein (CETP) that leads to elevated high-density lipoprotein cholesterol levels .
    CP 524515
  • HY-N13235
    Garlic Extract

    		Bacterial Antibiotic Cardiovascular Disease
    Garlic Extract is a garlic extract, and its components include: Allicin. Garlic Extract is beneficial to cardiovascular disease and has the potential to reduce the risk of cardiovascular disease. Garlic Extract can effectively reduce total cholesterol, low-density lipoprotein levels and improve high-density lipoprotein levels. .
    Garlic Extract
  • HY-106278A
    GW 590735 sodium

    		PPAR Metabolic Disease
    GW 590735 sodium is a potent and selective PPARα agonist with activity in regulating lipid metabolism. GW 590735 significantly increased high-density lipoprotein (HDL) cholesterol, decreased low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) cholesterol, and significantly reduced triglycerides. The maximum increases in HDL cholesterol for GW 590735 were 37%, 53% and 84%, respectively, compared with bezafibrate, torcetrapib and GW 590735 .
    GW 590735 sodium
  • HY-109567A
    Gemcabene calcium

    PD-72953 calcium

    		 LDLR Metabolic Disease Inflammation/Immunology
    Gemcabene calcium (PD-72953 calcium), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene calcium
  • HY-100901
    CDD3505

    		Cytochrome P450 Metabolic Disease
    CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
    CDD3505
  • HY-121776
    Nicomol

    		Drug Derivative Cardiovascular Disease
    Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
    Nicomol
  • HY-120984
    Oleic Acid-2,6-diisopropylanilide

    		Endogenous Metabolite Metabolic Disease
    AcylCoA:cholesterol acyltransferase (ACAT) is an intracellular cholesteryl ester synthase tied closely to the absorption of dietary cholesterol.1 Oleic acid-2,6-diisopropylanilide is an inhibitor of acylCoA:cholesterol acyltransferase with an IC50 of 7 nM.2 When co-administered to rabbits or rats fed a high fat, high cholesterol diet, oleic acid-2,6-diisopropylanilide decreased low density lipoproteins and elevated high density lipoprotein levels when administered at 0.05%.
    Oleic Acid-2,6-diisopropylanilide
  • HY-121776R
    Nicomol (Standard)

    		Drug Derivative Reference Standards Cardiovascular Disease
    Nicomol (Standard) is the analytical standard of Nicomol. This product is intended for research and analytical applications. Nicomol is an orally active hypolipidemic agent that can increase the high density lipoprotein cholesterol (HDL-C) level. Nicomol inhibits the rapid rise of plasma free fatty acids .
    Nicomol (Standard)
  • HY-117459
    E-3030 free acid

    		PPAR Metabolic Disease
    E-3030 free acid is a potent dual activator of peroxisome proliferator-activated receptor (PPAR) alpha and PPARgamma, exhibiting significant antidiabetic and lipid-modulating effects. E-3030 decreases blood glucose, triglyceride, non-esterified fatty acids, and insulin levels, while increasing blood adiponectin levels. E-3030 improves glucose tolerance and shows remarkable triglyceride- and non-high-density lipoprotein cholesterol-lowering effects in animal models.
    E-3030 free acid
  • HY-42680A
    Tagatose

    		Biochemical Assay Reagents Metabolic Disease
    Tagatose is a low-calorie sugar substitute. Tagatose exhibits beneficial effects on postprandial hyperglycaemia and hyperinsulinaemia. Tagatose can induce weight loss and raise high-density lipoprotein cholesterol. Tagatose has antioxidant activity. Tagatose can be studied in research on type 2 diabetes and obesity .
    Tagatose
  • HY-109567R
    Gemcabene (Standard)

    PD-72953 (Standard)

    		 Others Reference Standards Metabolic Disease Inflammation/Immunology
    Gemcabene (Standard) is the analytical standard of Gemcabene. This product is intended for research and analytical applications. Gemcabene (PD-72953), a first-in-class lipid-lowering agent, lowers low-density lipoprotein cholesterol (LDL-C), decreases triglycerides, and raises high-density lipoprotein cholesterol (HDL-C) and lowers pro-inflammatory acute-phase protein, C-reactive protein (CRP), exerting anti-inflammatory activity .
    Gemcabene (Standard)
  • HY-P2752A
    Lipoprotein Lipase, Bovine

    		Endogenous Metabolite Metabolic Disease
    Lipoprotein lipase, Bovine (EC 3.1.1.34) belongs to the lipase gene family and is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins (such as those in chylomicrons and very low-density lipoproteins (VLDL)) into two free fatty acid molecules and one monoacylglycerol molecule. Lipoprotein also participates in promoting cellular uptake of chylomicron remnants, cholesterol-rich lipoproteins, and free fatty acids. Lipoprotein requires ApoC-II as a cofactor. Lipoprotein attaches to the luminal surface of capillary endothelial cells via glycosylphosphatidylinositol high-density lipoprotein-binding protein 1 (GPIHBP1) and heparan sulfate proteoglycan.
    Lipoprotein Lipase, Bovine
  • HY-P2752B
    Lipoprotein Lipase, Burkholderia sp.

    		Endogenous Metabolite Metabolic Disease
    Lipoprotein Lipase, Burkholderia sp. (EC 3.1.1.34) belongs to the lipase gene family and is a water-soluble enzyme that hydrolyzes triglycerides in lipoproteins (such as those in chylomicrons and very low-density lipoproteins (VLDL)) into two free fatty acid molecules and one monoacylglycerol molecule. Lipoprotein also participates in promoting cellular uptake of chylomicron remnants, cholesterol-rich lipoproteins, and free fatty acids. Lipoprotein requires ApoC-II as a cofactor. Lipoprotein attaches to the luminal surface of capillary endothelial cells via glycosylphosphatidylinositol high-density lipoprotein-binding protein 1 (GPIHBP1) and heparan sulfate proteoglycan.
    Lipoprotein Lipase, Burkholderia sp.
  • HY-100901R
    CDD3505 (Standard)

    		Cytochrome P450 Reference Standards Metabolic Disease
    CDD3505 (Standard) is the analytical standard of CDD3505 (HY-100901). This product is intended for research and analytical applications. CDD3505 is used for elevating high density lipoprotein cholesterol (HDL) by inducing hepatic cytochrome P450IIIA (CYP3A) activity.
    CDD3505 (Standard)
  • HY-18778B
    Obicetrapib potassium

    TA-8995 potassium; DEZ-001 potassium; AMG-899 potassium

    		 Apolipoprotein CETP LPL Receptor LDLR Metabolic Disease
    Obicetrapib (TA-8995; DEZ-001) potassium is an orally active cholesteryl ester transfer protein (CETP) inhibitor. Obicetrapib potassium potently reduces atherogenic lipoproteins (such as LDL-C, ApoB, Lp (a)) and increases HDL-C. Obicetrapib potassium can be used for the research of dyslipidemia and atherosclerotic cardiovascular disease (ASCVD) .
    Obicetrapib potassium

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: